Acetyl-NFE2L2 (K599) Antibody

What is the specificity of Acetyl-NFE2L2 (K599) Antibody?

Acetyl-NFE2L2 (K599) Polyclonal Antibody is highly specific, detecting endogenous levels of NFE2L2 (NRF2) protein only when acetylated at lysine 599. This antibody has been affinity-purified from rabbit antiserum using epitope-specific immunogen derived from the C-terminal region of human NFE2L2 around the acetylation site of K599 . The antibody shows reactivity with human, mouse, and rat samples, making it versatile for comparative studies across species . Validation data from Western blot analysis of A549 cells confirms its specificity for the acetylated form of NFE2L2 .

What is the biological significance of NFE2L2 acetylation at K599?

NFE2L2 acetylation at K599 (human numbering) represents a critical post-translational modification that enhances the transcriptional activity of this master regulator of cellular defense. Studies have shown that acetylation of NFE2L2 by CREB at K599 augments its binding to antioxidant response elements (AREs), thereby increasing the expression of cytoprotective genes . In murine models, this corresponds to acetylation at K591 (equivalent to human K599) . This modification is particularly important during oxidative stress responses, as it helps stabilize NFE2L2 nuclear localization and enhances its ability to recruit transcriptional co-activators . The acetylation status at this residue can serve as a biomarker for NFE2L2 activation in various experimental conditions.

What are the validated experimental applications for Acetyl-NFE2L2 (K599) Antibody?

The antibody has been most thoroughly validated for Western blot applications, where it shows consistent detection of acetylated NFE2L2 at K599. Researchers should note that while ELISA applications are possible, they require higher dilution due to increased sensitivity of the assay .

How should samples be prepared to optimize detection of acetylated NFE2L2?

For optimal detection of acetylated NFE2L2, samples should be prepared with the following considerations:

• Protein Extraction: Use a lysis buffer containing phosphatase and deacetylase inhibitors (e.g., sodium butyrate, trichostatin A, or nicotinamide) to prevent loss of acetylation during sample preparation.

• Nuclear Extraction: Since NFE2L2 translocates to the nucleus upon activation, nuclear extraction protocols often yield better results for detecting the acetylated form. A two-step extraction process separating cytoplasmic and nuclear fractions is recommended.

• Sample Treatment: To increase acetylation levels for positive controls, cells can be treated with deacetylase inhibitors (HDACi) or oxidative stress inducers like sulforaphane, dimethyl fumarate, or hydrogen peroxide, which have been shown to increase NFE2L2 acetylation levels and activity .

• Storage Conditions: Store samples at -80°C with protease inhibitors to prevent degradation. Avoid repeated freeze-thaw cycles which can affect protein integrity and post-translational modifications.

How can Acetyl-NFE2L2 (K599) Antibody be used to investigate the relationship between NFE2L2 acetylation and autophagy?

Recent research has established that NFE2L2 is a key regulator of autophagy gene expression. Researchers can employ Acetyl-NFE2L2 (K599) Antibody to elucidate the specific role of K599 acetylation in this process through the following approaches:

• Comparative Analysis: Compare acetylation levels at K599 during basal conditions versus induced autophagy (starvation, rapamycin treatment) using Western blot analysis.

• ChIP-seq Experiments: Use Acetyl-NFE2L2 (K599) Antibody for chromatin immunoprecipitation followed by sequencing to identify genome-wide binding sites of acetylated NFE2L2 on autophagy-related gene promoters containing antioxidant response elements (AREs).

• Co-Immunoprecipitation Studies: Investigate interactions between acetylated NFE2L2 and autophagy-related proteins such as SQSTM1/p62, which has been shown to interact with KEAP1 and potentially regulate NFE2L2 activity .

Evidence indicates that NFE2L2 directly regulates the expression of autophagy genes including SQSTM1/p62, ULK1, ATG5, and GABARAPL1 by binding to AREs in their promoter regions . The acetylation status at K599 may influence this regulatory function, potentially serving as a molecular switch that coordinates redox homeostasis with autophagy activation.

What is the role of NFE2L2 K599 acetylation in cancer development and chemoresistance?

NFE2L2 acetylation at K599 may play a significant role in cancer pathogenesis and response to therapy as evidenced by:

Research designs investigating this relationship should incorporate Acetyl-NFE2L2 (K599) Antibody in immunohistochemical analyses of tumor biopsies, correlation studies with patient outcomes, and in vitro drug response assays using cell lines with varying levels of NFE2L2 acetylation .

How can researchers validate the specificity of Acetyl-NFE2L2 (K599) Antibody in their experimental systems?

To ensure experimental rigor, researchers should implement the following validation strategies:

• Positive and Negative Controls:

  • Positive control: Cells treated with CREB activators or deacetylase inhibitors to induce NFE2L2 acetylation

  • Negative control: NFE2L2 knockout cells or cells expressing a K599R mutant NFE2L2 (lysine to arginine) that cannot be acetylated

• Competition Assays: Pre-incubate the antibody with the immunizing peptide (acetylated K599 peptide) before applying to Western blot or immunostaining to confirm binding specificity.

• Comparison with Total NFE2L2 Antibody: Run parallel assays with both acetyl-specific and total NFE2L2 antibodies to compare detection patterns and relative levels.

• Mass Spectrometry Verification: For definitive validation, immunoprecipitate NFE2L2 and perform mass spectrometry to confirm acetylation at K599 in your experimental conditions.

What are common troubleshooting issues when working with Acetyl-NFE2L2 (K599) Antibody and how can they be resolved?

How does NFE2L2 acetylation at K599 interact with other post-translational modifications?

NFE2L2 is subject to multiple post-translational modifications that work in concert to regulate its activity. The relationship between K599 acetylation and other modifications includes:

• Phosphorylation Crosstalk: Phosphorylation at Ser40 by PKCδ and PKCι facilitates NFE2L2 release from KEAP1, while subsequent acetylation at K599 by CREB enhances DNA binding activity. These modifications operate in sequence to fully activate NFE2L2 . Similarly, AMPK-mediated phosphorylation at Ser558 may work synergistically with K599 acetylation to promote nuclear localization and transcriptional activity .

• Ubiquitination Competition: Acetylation at K599 may prevent ubiquitination at nearby lysine residues, thereby increasing NFE2L2 stability. Under normal conditions, NFE2L2 is ubiquitinated at seven lysine residues situated between the KEAP1 binding sites, leading to proteasomal degradation .

• SUMOylation Enhancement: Research suggests that acetylation of NFE2L2 may facilitate subsequent SUMOylation, which is needed for efficient ARE binding .

Understanding this interplay requires careful experimental design that monitors multiple modifications simultaneously, potentially using combination approaches with phospho-specific and acetyl-specific antibodies in sequential immunoprecipitation experiments.

What is the mechanism by which stress conditions regulate NFE2L2 acetylation at K599?

The acetylation of NFE2L2 at K599 is regulated by stress conditions through a multi-step process:

• Oxidative Stress Sensing: Oxidative or electrophilic stress modifies critical cysteine residues in KEAP1 (particularly Cys-151, 257, 273, 288, 297, and 433), disrupting the KEAP1-NFE2L2 interaction . This prevents NFE2L2 ubiquitination and subsequent degradation.

• Nuclear Translocation: Stabilized NFE2L2 translocates to the nucleus, assisted by karyopherins α1 and β1 through the nuclear pore complex .

• Acetyltransferase Recruitment: Within the nucleus, NFE2L2 interacts with acetyltransferases such as CREB, which directly augments NFE2L2 binding to AREs by acetylating lysine residues including K596 and K599 .

• Transcriptional Complex Formation: Acetylated NFE2L2 forms heterodimers with small MAF proteins (MAFF, MAFG, and MAFK) and binds to AREs in the promoter regions of target genes .

• Temporal Regulation: The duration of NFE2L2 acetylation and activity appears to be age-dependent; for example, tert-Butylquinone promotes ARE binding for only 30 minutes in primary astrocytes from old rats, whereas this extends to 3 hours in cells from young animals .

This intricate regulatory mechanism explains why the acetylation status of NFE2L2 at K599 serves as an important biomarker for cellular stress responses and potentially for aging-related pathologies.

How is acetylated NFE2L2 implicated in neurodegenerative diseases, particularly Alzheimer's disease?

Research indicates that acetylated NFE2L2 plays a significant role in neurodegenerative disorders, especially Alzheimer's disease (AD):

• Proteostasis Regulation: Acetylated NFE2L2 regulates the expression of autophagy genes crucial for clearance of protein aggregates characteristic of AD. Studies in mouse models of AD show that NFE2L2 deficiency leads to increased intracellular aggregates of amyloid precursor protein (APP) and tau protein .

• Autophagy Marker Co-localization: In NFE2L2-deficient mice co-expressing HsAPP V717I and HsMAPT P301L (tau), colocalization of these AD-associated proteins with the NFE2L2-regulated autophagy marker SQSTM1/p62 was reduced, suggesting impaired clearance mechanisms .

• Human AD Tissue Evidence: In AD patients, neurons expressing high levels of APP or MAPT also expressed SQSTM1/p62 and nuclear NFE2L2, suggesting an attempt to degrade intraneuronal aggregates through autophagy .

• Age-Related Decline: The decreased ability of NFE2L2 to remain active in aged cells (30 minutes versus 3 hours in young cells) may contribute to the age-dependent risk of AD development .

Research using Acetyl-NFE2L2 (K599) Antibody could help determine whether acetylation status influences NFE2L2's ability to promote autophagy and clear protein aggregates in neurodegenerative conditions, potentially identifying new therapeutic strategies that enhance NFE2L2 acetylation.

What is the experimental evidence linking NFE2L2 acetylation to age-related macular degeneration (AMD)?

The connection between NFE2L2 acetylation and age-related macular degeneration is supported by several lines of experimental evidence:

• Oxidative Stress in RPE: Oxidative stress damages retinal pigment epithelium (RPE) and contributes to AMD progression. NFE2L2 activation, potentially through acetylation at K599, has been shown to protect against oxidative damage in RPE cells .

• Autophagy Regulation: NFE2L2 regulates autophagy genes that are critical for maintaining RPE homeostasis. For example, polyunsaturated fatty acids transiently increase ROS in RPE cells and induce both NFE2L2 and autophagy protein SQSTM1/p62 .

• EMT and Fibrosis: Epithelial-to-mesenchymal transition (EMT) leads to fibrosis in RPE, a characteristic of AMD. Many pathways triggering EMT are promoted by oxidative stress, which is counteracted by NFE2L2 activity .

• Age-Dependent Decline: The age-dependent decline in NFE2L2 activity may contribute to AMD susceptibility in elderly populations. Factors like BACH and c-MYC increase with aging and may decrease NFE2L2-ARE signaling .

• Environmental Triggers: Smoking, a significant environmental risk factor for AMD, contains compounds like acrolein, cadmium, and hydroquinone that cause oxidative damage. The KEAP1-NFE2L2 pathway plays a prominent role in mounting the anti-oxidant defense against these compounds in retinal cells .

Research utilizing Acetyl-NFE2L2 (K599) Antibody could help elucidate whether specific acetylation at K599 correlates with RPE protection or vulnerability to AMD-associated stressors, potentially leading to novel therapeutic approaches targeting this modification.

How can CRISPR-Cas9 technology be used in conjunction with Acetyl-NFE2L2 (K599) Antibody to study site-specific acetylation effects?

CRISPR-Cas9 technology offers powerful approaches to study the specific role of K599 acetylation when used alongside Acetyl-NFE2L2 (K599) Antibody:

• Site-Directed Mutagenesis: Generate K599R or K599Q knock-in cell lines (arginine prevents acetylation while glutamine mimics constitutive acetylation) to study the functional consequences of this specific modification.

• CRISPRa/CRISPRi for Acetyltransferases: Use CRISPR activation (CRISPRa) or interference (CRISPRi) to modulate expression of acetyltransferases that target K599, such as CREB-binding protein (CBP), and then monitor effects on NFE2L2 acetylation using the specific antibody.

• Epigenetic Editing: Deploy CRISPR-based epigenetic editors to specifically modify the chromatin environment around NFE2L2-regulated genes and assess how K599 acetylation status affects accessibility to these modified regions.

• High-Throughput Screening: Combine CRISPR library screens with Acetyl-NFE2L2 (K599) Antibody-based readouts to identify novel regulators of NFE2L2 acetylation.

An example experimental workflow could involve:

• Creating cell lines with K599R mutation

• Challenging with oxidative stress inducers like sulforaphane or hydrogen peroxide

• Immunoprecipitating with Acetyl-NFE2L2 (K599) Antibody

• Performing RNA-seq to identify genes differentially regulated when K599 acetylation is prevented

• Validating findings using ChIP-seq with the same antibody

What multiplexed imaging approaches can be used with Acetyl-NFE2L2 (K599) Antibody to study its subcellular localization?

Advanced multiplexed imaging techniques can provide comprehensive insights into acetylated NFE2L2 localization and function:

• Multi-Epitope Ligand Cartography (MELC): This technique allows sequential immunofluorescence staining of the same sample with up to 100 antibodies. Researchers can use Acetyl-NFE2L2 (K599) Antibody alongside antibodies against nuclear markers, other transcription factors, and target genes to create detailed spatial maps of acetylated NFE2L2 activity.

• Proximity Ligation Assay (PLA): Combine Acetyl-NFE2L2 (K599) Antibody with antibodies against potential interaction partners (like small MAF proteins, CREB, or histone acetyltransferases) to visualize and quantify molecular interactions within 40 nm proximity in situ.

• Mass Cytometry Imaging (IMC): Label Acetyl-NFE2L2 (K599) Antibody with rare earth metals and use alongside metal-labeled antibodies against other proteins to achieve highly multiplexed imaging with subcellular resolution.

• Live-Cell FRET Sensors: While not directly using the antibody, complementary approaches include developing FRET-based sensors for real-time monitoring of NFE2L2 acetylation dynamics in living cells.

Implementation example:

• Co-stain fixed cells or tissue sections with Acetyl-NFE2L2 (K599) Antibody (1:100 dilution) and antibodies against nuclear pore complexes, chromatin markers, and transcriptional machinery

• Apply super-resolution microscopy techniques like STORM or STED

• Quantify the spatial distribution of acetylated NFE2L2 relative to chromatin states and nuclear landmarks

• Correlate with transcriptional activity of target genes

These approaches can reveal how the acetylation of NFE2L2 at K599 influences its nuclear organization and association with transcriptional complexes under various physiological and stress conditions.